Literature DB >> 18365834

Alternative macrophage activation in periprosthetic osteolysis.

P Edward Purdue1.   

Abstract

Several disorders characterized by macrophages accumulating non-disposable (or hard to dispose of) material or formation of multinucleated giant cell containing granulomas have been linked to elicitation of an alternative macrophage activation phenotype. Gene profiling efforts have shown that alternative macrophage activation can exist in numerous forms, each specific for the particular biological niche in which the macrophage finds itself, accentuating the plasticity of this cell type. Periprosthetic osteolysis is characterized by macrophage phagocytosis of particles of wear debris and formation of foreign body granulomas, suggesting the hypothesis that it may represent a new member of this group of diseases characterized by alternative macrophage activation. Gene profiling has provided strong supportive evidence for this hypothesis, revealing that periprosthetic tissues of osteolysis patients show the presence of a pronounced alternative macrophage activation pathway, with the classical pro-inflammatory activation pathway being less evident. These findings have important implications for our understanding of periprosthetic osteolysis and how to approach future investigations into this disease.

Entities:  

Mesh:

Year:  2008        PMID: 18365834     DOI: 10.1080/08916930701694626

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  9 in total

1.  Role of macrophages in the biological reaction to wear debris from joint replacements.

Authors:  Christophe Nich; Stuart B Goodman
Journal:  J Long Term Eff Med Implants       Date:  2014

Review 2.  Macrophages-Key cells in the response to wear debris from joint replacements.

Authors:  Christophe Nich; Yuya Takakubo; Jukka Pajarinen; Mari Ainola; Abdelhakim Salem; Tarvo Sillat; Allison J Rao; Milan Raska; Yasunobu Tamaki; Michiaki Takagi; Yrjö T Konttinen; Stuart B Goodman; Jiri Gallo
Journal:  J Biomed Mater Res A       Date:  2013-04-09       Impact factor: 4.396

3.  Revision joint replacement, wear particles, and macrophage polarization.

Authors:  Allison J Rao; Emmanuel Gibon; Ting Ma; Zhenyu Yao; R Lane Smith; Stuart B Goodman
Journal:  Acta Biomater       Date:  2012-04-03       Impact factor: 8.947

Review 4.  Mechano-Immunomodulation: Mechanoresponsive Changes in Macrophage Activity and Polarization.

Authors:  Sarah Adams; Leah M Wuescher; Randall Worth; Eda Yildirim-Ayan
Journal:  Ann Biomed Eng       Date:  2019-06-19       Impact factor: 3.934

5.  Photoluminescent carbon dots (PCDs) from sour apple: a biocompatible nanomaterial for preventing UHMWPE wear-particle induced osteolysis via modulating Chemerin/ChemR23 and SIRT1 signaling pathway and its bioimaging application.

Authors:  Xiang Li; Yang Lu; Jiarui Li; Shengji Zhou; Yuxin Wang; Liangping Li; Fengchao Zhao
Journal:  J Nanobiotechnology       Date:  2022-06-27       Impact factor: 9.429

6.  Local effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine calvarium.

Authors:  Allison J Rao; Christophe Nich; Lakshmi S Dhulipala; Emmanuel Gibon; Roberto Valladares; Stefan Zwingenberger; R Lane Smith; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2012-12-05       Impact factor: 4.396

7.  An Alternative Macrophage Activation Pathway Regulator, CHIT1, May Provide a Serum and Synovial Fluid Biomarker of Periprosthetic Osteolysis.

Authors:  Samir K Trehan; Lester Zambrana; Jonathan E Jo; Ed Purdue; Athanos Karamitros; Joseph T Nguyen; Joseph M Lane
Journal:  HSS J       Date:  2017-12-26

Review 8.  The role of TLR and chemokine in wear particle-induced aseptic loosening.

Authors:  Qiaoli Gu; Qin Shi; Huilin Yang
Journal:  J Biomed Biotechnol       Date:  2012-10-21

Review 9.  Disease-Associated Particulates and Joint Inflammation; Mechanistic Insights and Potential Therapeutic Targets.

Authors:  Olwyn R Mahon; Aisling Dunne
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.